Guselkumab
Treatment for Psoriasis
Typical Dosage: 100mg SC at weeks 0, 4, then every 8 weeks
Effectiveness
88%
Safety Score
60%
Clinical Trials
61
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
100mg SC at weeks 0, 4, then every 8 weeks
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
80(Treat 80 patients to see 1 additional serious adverse event)
Confidence Score
93%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$97,000
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$98,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$155,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$116,786
Cost per Remission
$245,250
Guselkumab Outcomes
for Psoriasis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+84%
Remission Rate
+40%
Common Side Effects
Upper respiratory tract infection
+12.6%
Headache
+10.4%
Injection site reactions
+7.5%
Gastroenteritis
+3.4%
Active Clinical Trials
8 active trials recruiting for Guselkumab in Psoriasis
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
NCT07532486RECRUITINGNA
400 participants
INTERVENTIONAL
Hangzhou, China
Started: Jul 10, 2024
Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
NCT07430319RECRUITING
100 participants
OBSERVATIONAL
Nice, France
Started: Oct 16, 2025
Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.
NCT06974474RECRUITINGPHASE4
26 participants
INTERVENTIONAL
Rome, Italy
Started: Jun 18, 2024
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
NCT03451851ACTIVE NOT RECRUITINGPHASE3
120 participants
INTERVENTIONAL
Palo Alto, United States +38 more
Started: Jul 11, 2018
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT05270733RECRUITINGPHASE4
56 participants
INTERVENTIONAL
Cleveland, United States
Started: Nov 10, 2022
Immune Spatial Features of Guselkumab Cutaneous Response
NCT05858632RECRUITINGPHASE4
10 participants
INTERVENTIONAL
San Francisco, United States
Started: Jul 1, 2023
A Phase 3 Clinical Study of QL2106 Injection
NCT07511647RECRUITINGPHASE3
318 participants
INTERVENTIONAL
Jining, China
Started: Jun 15, 2026
Multi-Center PAMPA Study
NCT05004727RECRUITINGPHASE4
176 participants
INTERVENTIONAL
Boston, United States +4 more
Started: Feb 16, 2022
Completed Clinical Trials
9 completed trials for Guselkumab in Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
NCT02325219COMPLETEDPHASE3
192 participants
INTERVENTIONAL
Asahikawa, Japan +26 more
Started: Dec 19, 2014
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
NCT04439526COMPLETED
356 participants
OBSERVATIONAL
Bari, Italy +37 more
Started: Jun 10, 2020
Guselkumab Immunogenetics
NCT04645355COMPLETEDPHASE4
17 participants
INTERVENTIONAL
San Francisco, United States
Started: Mar 1, 2021
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
NCT04914429COMPLETEDPHASE4
327 participants
INTERVENTIONAL
Beijing, China +25 more
Started: Aug 25, 2021
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT02343744COMPLETEDPHASE3
21 participants
INTERVENTIONAL
Asahikawa, Japan +19 more
Started: Jan 19, 2015
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
NCT05272150COMPLETEDPHASE3
211 participants
INTERVENTIONAL
Birmingham, United States +93 more
Started: Jul 13, 2022
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
NCT02905331COMPLETEDPHASE3
78 participants
INTERVENTIONAL
Ocala, United States +13 more
Started: Feb 28, 2017
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
NCT03818035COMPLETEDPHASE3
880 participants
INTERVENTIONAL
Antony, France +89 more
Started: Feb 8, 2019
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189COMPLETEDPHASE3
338 participants
INTERVENTIONAL
Birmingham, United States +63 more
Started: Aug 24, 2023
Showing 20 of 72 total trials